&Partners’s AstraZeneca AZN Stock Holding History

&Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19M	Buy	99,983 +29,618	+42%	+$5.57M	0.08%	233
2026 Q1	$13.9M	Buy	70,365 +2,803	+4%	+$540K	0.07%	264
2025 Q4	$12.4M	Buy	67,562 +10,932	+19%	+$1.92M	0.07%	265
2025 Q3	$8.69M	Buy	56,630 +3,977	+8%	+$602K	0.06%	295
2025 Q2	$7.36M	Buy	52,653 +9,411	+22%	+$1.32M	0.06%	290
2025 Q1	$6.42M	Sell	43,242 -2,748	-6%	-$398K	0.07%	250
2024 Q4	$6.08M	Buy	45,990 +18,790	+69%	+$2.63M	0.07%	248
2024 Q3	$4.24M	Buy	27,200 +19,389	+248%	+$3.13M	0.08%	229
2024 Q2	$1.22M	Buy	+7,811	New	+$1.18M	0.05%	298

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

&Partners's AZN Position: Q2 2026 in Review

&Partners increased its AstraZeneca (AZN) stake by 42% in Q2 2026, buying an estimated $5.57M and bringing the position to 99,983 shares worth $19M. The position accounts for 0.08% of the portfolio, ranked #233.

&Partners first reported a position in AZN in Q2 2024 and has held it in 9 quarters since. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

&Partners held 99,983 shares of AstraZeneca worth $19M as of Q2 2026.
&Partners bought 29,618 AstraZeneca shares in Q2 2026, an estimated $5.57M.
AstraZeneca made up 0.08% of &Partners's portfolio in Q2 2026, its #233 holding.
&Partners first reported a position in AstraZeneca in Q2 2024 and has held it in 9 quarters since.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.